Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Fuction | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29852015 | 2018 | GLRKRLRKFRNKDKEKLKKIGQKIQGLLPKLAPRTDY | Peptide 3 | Free | Free | Linear | L | None | 37 | NA | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKDKKIGQKIQGLLPKLAPRTDY | Peptide 16 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKPKKIGQKIQGLLPKLAPRTDY | Peptide 18 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKDQGLLPKLAPRTDY | Peptide 26 | Free | Free | Linear | L | None | 37 | NA | 0 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 29852015 | 2018 | GLRKRLRKFRNKIKEKLKKIGQKNQGLLPKLAPRTDY | Peptide 28 | Free | Free | Linear | L | None | 37 | NA | 1 % Hemolysis at 64 μg/ml | Horse | Cap18 Derivatives | NA | Non-hemolytic | ||
| 30108987 | 2018 | {nnr:KP}WW{nnr:KP}WW{nnr:KP}WW{nnr:KP}{nt:H}{ct:Amid} | CAP13 | Amidation | H | Linear | L | KP = phosphonium isostere of (trimethyl)lysine | 10 | NA | 11.0 ± 1.6 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | NA | ||
| 30108987 | 2018 | {nnr:RP}WW{nnr:RP}WW{nnr:RP}WW{nnr:RP}{nt:H}{ct:Amid} | CAP14 | Amidation | H | Linear | L | RP = phosphonium side chain length comparable o that of arginine | 10 | NA | 5.8 ± 1.0 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | NA | ||
| 30108987 | 2018 | {nnr:KP}LL{nnr:KP}LL{nnr:KP}LL{nnr:KP}{nt:H}{ct:Amid} | CAP15 | Amidation | H | Linear | L | KP = phosphonium isostere of (trimethyl)lysine | 10 | NA | 2.1 ± 0.5 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | Low hemolytic | ||
| 30108987 | 2018 | {nnr:RP}LL{nnr:RP}LL{nnr:RP}LL{nnr:RP}{nt:H}{ct:Amid} | CAP16 | Amidation | H | Linear | L | RP = phosphonium side chain length comparable o that of arginine | 10 | NA | 0.6 ± 0.2 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | Non-hemolytic | ||
| 30108987 | 2018 | {nnr:KP}II{nnr:KP}II{nnr:KP}II{nnr:KP}{nt:H}{ct:Amid} | CAP17 | Amidation | H | Linear | L | KP = phosphonium isostere of (trimethyl)lysine | 10 | NA | 2.3 ± 1.5 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | Low hemolytic | ||
| 30108987 | 2018 | {nnr:RP}II{nnr:RP}II{nnr:RP}II{nnr:RP}{nt:H}{ct:Amid} | CAP18 | Amidation | H | Linear | L | RP = phosphonium side chain length comparable o that of arginine | 10 | NA | 3.9 ± 0.7 % Hemolysis at 512 μM | Horse | Phosphonium Based Cationic Amphiphilic Peptides | NA | Low hemolytic | ||
| 30052685 | 2018 | KKLFKKK({nnr:COC3H7})LKYL{nt:Acet}{ct:Amid} | BP386 | Amidation | Acetylation | Linear | L | COC3H7 = butanoyl | 11 | NA | 1 ± 0.1 % Hemolysis at 250 μM | Horse | Cecropin A-Melittin Hybrid Peptide | NA | Non-hemolytic | ||
| 30052685 | 2018 | KKLFKKK({nnr:COC3H7})LKYL{nt:Acet}{ct:Amid} | BP386 | Amidation | Acetylation | Linear | L | COC3H7 = butanoyl | 11 | NA | 3 ± 0 % Hemolysis at 375 μM | Horse | Cecropin A-Melittin Hybrid Peptide | NA | Non-hemolytic | ||
| 30105347 | 2018 | ADLPFE{d}F | PapR7-dE | Free | Free | Linear | Mix | e = D-glutamic acid | 7 | NA | 50 % Hemolysis at 1 μM | Human | Synthetic Peptide | NA | NA | ||
| 30161192 | 2018 | SLTFEVLDKVLGELGKVSRK | StI12-31 | Free | Free | Linear | L | None | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin I | α-Helical | Non-hemolytic | ||
| 30161192 | 2018 | SLTFQVLDKVLEELGKVSRK | StII11-30 | Free | Free | Linear | L | None | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin Ii | α-Helical | Non-hemolytic | ||
| 30161192 | 2018 | {nnr:TOAC}-SLTFQVLDKVLEELGKVSRK{nt:TOAC} | N-TOAC-StII11-30 | Free | TOAC | Linear | L | TOAC = 2,2,6,6-tetramethyl-N-oxyl-4-amino-4-carboxylic acid | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin Ii | α-Helical | Non-hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 25 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 50 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 75 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 1 % Hemolysis at 100 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30476118 | 2019 | FTKIIHKLKKFIRYRKVLRWSRMWWVLLVREIVGDN{ct:Amid} | EXP2-HD | Amidation | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 10.71 µM | Human | Synthetic Peptide | NA | NA | ||
| 30690103 | 2019 | LEAAPKKVQDLLKKANITVKGAFQLFS{nt:Amid} | BAR | Free | Amidation | Linear | L | None | 27 | NA | 0 % Hemolysis at 3.4 µM | Sheep | Bacteria Sspb (Antigen I/Ii) Protein Of Streptococcus Gordonii (Sg) | NA | Non-hemolytic | ||
| 30690103 | 2019 | LEAAPKKVQDLLKKANITVKGAFQLFS{nt:Amid} | BAR | Free | Amidation | Linear | L | None | 27 | NA | 0 % Hemolysis at 1.3 µM | Sheep | Bacteria Sspb (Antigen I/Ii) Protein Of Streptococcus Gordonii (Sg) | NA | Non-hemolytic | ||
| 30127331 | 2019 | FLPFFAACAITRKC{ct:heptapeptide ring C8-C14} | Amurin-9KY2 | heptapeptide ring C8-C14 | Free | Linear | L | None | 14 | NA | 17.9 % Hemolysis at 100 μg/mL | Human | Derived From Amurin-9Ky | NA | NA | ||
| 30127331 | 2019 | FLPFFAACAITRKC | Amurin-9KY3 | Free | Free | Linear | L | None | 14 | NA | 20.8 % Hemolysis at 100 μg/mL | Human | Derived From Amurin-9Ky | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 0.38 ± 0.17 (n at 5) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.93 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.23 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.74 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.44 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.27 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.16 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | ~45 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.39 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.19 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.47 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.84 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 0.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.42 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.01 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.76 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG{nnr:M sulfone}IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.56 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at 50 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 10.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.68 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 ± 0.25 (n at 8) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.86 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.6 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.13 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | ~70 % Hemolysis at 0.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | ~60% % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.09 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at 1.92 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at 1.22 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at 28 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.78 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.90 ± 0.19 (n at 8) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.77 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at 0.75 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at 1.61 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKR | 37g | Free | Free | Linear | L | None | 30 | NA | 50 % Hemolysis at 7.8 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.58 ± 0.17 (n at 10) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.91 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 2.3 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK{ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.58 ± 0.2 (n at6) µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.12 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.62 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~50 % Hemolysis at 1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2.98 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.18 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.07 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.17 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.06 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.79 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 1.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.97 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.6 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.91 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.15 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.08 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.4 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.11 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.73 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at >20 (n at 5) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.16 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.67 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.78 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.27 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.93 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >80 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.09 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.55 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.18 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.43 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.03 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.99 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG(M sulfone)IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.65 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.83 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.14 ± 0.73 (n at 8) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.26 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.05 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 7.9 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 8) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 6.82 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKR | 37g | Free | Free | Linear | L | None | 30 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 10) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 1.51 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK(Stearoyl){ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.94 ± 0.4 (n at 6) µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~60 % Hemolysis at 5 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 4.32 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.12 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 3.97 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | ~35 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.41 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.19 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.35 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.99 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 12.8 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.07 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31261655 | 2019 | MFTLKKSLLLLFFLGMVSLSLCEQERDADEDDNACEAKVENVKRVARPPGFTPFRVAPEIV | RVA-Thr6-BK | Free | Free | Linear | L | None | 61 | NA | 0 % Hemolysis at 256 μM | Horse | Frog Odorrana Hejiangensis | NA | Non-hemolytic | ||
| 31261655 | 2019 | MFTSKKSILLLFFLGAISLSLCEEERDADEDDTEGEAKVENVKRVALPPGFTPFRVAPEIV | RVA-Leu1, Thr6-BK | Free | Free | Linear | L | None | 61 | NA | 0 % Hemolysis at 256 μM | Horse | Frog Amolops Wuyiensis | NA | Non-hemolytic | ||
| 32229648 | 2020 | AHFLPPIIRA{ct:Amid} | Dq-1133 | Amidation | Free | Linear | L | None | 10 | NA | 0 % Hemolysis at 10 μM | Rat | Giant Ant Dinoponera Quadriceps | NA | Non-hemolytic | ||
| 32229648 | 2020 | GVIPDDFRIR | Dq-1187 | Free | Free | Linear | L | None | 10 | NA | 0 % Hemolysis at 10 μM | Rat | Giant Ant Dinoponera Quadriceps | NA | Non-hemolytic | ||
| 32229648 | 2020 | AHFLPPIIRA{ct:Amid} | Dq-1133 | Amidation | Free | Linear | L | None | 10 | NA | 1.5 % Hemolysis at 50 μM | Rat | Giant Ant Dinoponera Quadriceps | NA | Non-hemolytic | ||
| 32229648 | 2020 | GVIPDDFRIR | Dq-1187 | Free | Free | Linear | L | None | 10 | NA | 0.3 % Hemolysis at 50 μM | Rat | Giant Ant Dinoponera Quadriceps | NA | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 19 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 11 % Hemolysis at 20 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 20 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 17 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0 % Hemolysis at 5 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0 % Hemolysis at 10 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0.6 % Hemolysis at 20 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 1 % Hemolysis at 40 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0 % Hemolysis at 5 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0 % Hemolysis at 10 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0.8 % Hemolysis at 20 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 1.1 % Hemolysis at 40 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32726461 | 2020 | VVEKAKEAAEHAKEAATKAL{nt:H}{ct:OH} | P1 | OH | H | Linear | L | None | 20 | NA | −1.84 ± 0.26 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | ΑΑΕΚΑΚEAAEHAKEVVTKVL{nt:H}{ct:OH} | P2 | OH | H | Linear | L | None | 20 | NA | 1.25 ± 0.65 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | ΑΑΕΚΑKEAAEHVKEVVTKVL{nt:H}{ct:OH} | P3 | OH | H | Linear | L | None | 20 | NA | −0.28 ± 0.49 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | AAEKAKEAVEHVKEVVTKVL{nt:H}{ct:OH} | P4 | OH | H | Linear | L | None | 20 | NA | 0.99 ± 0.66 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | AAEKAKEAVEHVKEFLTKVL{nt:H}{ct:OH} | P5 | OH | H | Linear | L | None | 20 | NA | 1.20 ± 0.78 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | ΑΑΕΚΑKEAVEHFKEFFTKFL{nt:H}{ct:OH} | P6 | OH | H | Linear | L | None | 20 | NA | −1.78 ± 0.17 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | AAEKLKEVAEHFKEFFTKVL{nt:H}{ct:OH} | P7 | OH | H | Linear | L | None | 20 | NA | −0.74 ± 0.41 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | VLEKVKEVVEHVKEVVTKVL{nt:H}{ct:OH} | P8 | OH | H | Linear | L | None | 20 | NA | −0.52 ± 0.49 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | VLEKLKELVEHVKEVVTKVL{nt:H}{ct:OH} | P9 | OH | H | Linear | L | None | 20 | NA | −0.37 ± 0.87 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | VLEKLKELVEHLKELVTKVL{nt:H}{ct:OH} | P10 | OH | H | Linear | L | None | 20 | NA | −0.41 ± 0.60 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | VLEKLKELLEHLKELLTKVL{nt:H}{ct:OH} | P11 | OH | H | Linear | L | None | 20 | NA | 1.64 ± 0.78 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | FFEKFKEFFEHFKEFFTKFF{nt:H}{ct:OH} | P13 | OH | H | Linear | L | None | 20 | NA | 1.99 ± 0.67 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | FFEKFKEFFEHFKEWWTKWL{nt:H}{ct:OH} | P14 | OH | H | Linear | L | None | 20 | NA | 2.63 ± 0.70 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = Disordered, 50% TFE = α‐Helical | Non-hemolytic | ||
| 32726461 | 2020 | FFEKFKEFWEHWKEWWTKWL{nt:H}{ct:OH} | P15 | OH | H | Linear | L | None | 20 | NA | 7.06 ± 0.86 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = α‐Helical, 50% TFE = α‐Helical and β‐Sheet | Low hemolytic | ||
| 32726461 | 2020 | FFEKWKEWWEHWKEWWTKWF{nt:H}{ct:OH} | P16 | OH | H | Linear | L | None | 20 | NA | 5.94 ± 0.58 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = α‐Helical, 50% TFE = α‐Helical and β‐Sheet | Low hemolytic | ||
| 32726461 | 2020 | WWEKWKEWWEHWKEWWTKWW{nt:H}{ct:OH} | P17 | OH | H | Linear | L | None | 20 | NA | 7.86 ± 0.64 % Hemolysis at 200 μM | mouse | Modfied Apoa‐I221–240 Synthetic Peptide | aqueous = α‐Helical, 50% TFE = α‐Helical and β‐Sheet | Low hemolytic | ||
| 33049300 | 2021 | RRGFFKPYGKKPKKVAKKPYYH | Gj-CATH3-(1–22)-peptide | Free | Free | Linear | L | None | 22 | NA | 9.54 ± 6.08 % Hemolysis at 80 μM | Sheep | Gj-Cath3 Analogues | NA | NA | ||
| 33830736 | 2021 | LRKSEEEVAARRARVVW | LP-1 | Free | Free | Linear | L | None | 17 | NA | 0 % Hemolysis at 100 µM | Human | Human Lactoferrin | α-Helical and β-Sheet | Non-hemolytic | ||
| 33798688 | 2021 | CLELLEELLELLEELLELLEEL | LZEP | Free | Free | Linear | L | None | 22 | NA | ~2.5 % Hemolysis at ~20 μM at pH 7.4 | Human | Synthetic Peptide | α-Helical | Low hemolytic | ||
| 33798688 | 2021 | CLELLEELLELLEELLELLEEL | LZEP | Free | Free | Linear | L | None | 22 | NA | 40 % Hemolysis at ~20 μM at pH 5 | Human | Synthetic Peptide | α-Helical | NA | ||
| 34282000 | 2021 | LLGDFF({nnr:Cit})KSKEKIGKEFK({nnr:Cit})IVQ({nnr:Cit})IKDFL({nnr:Cit})NLVP({nnr:Cit})TES | LL-37 Cit5 | Free | Free | Linear | L | Cit = citrulline | 37 | NA | 0 % Hemolysis at 80 μM | Human | Cathelicidins Modified Ll-37 | Helical | Non-hemolytic | ||
| 34164880 | 2021 | KL{nnr:X}KK{nnr:X}{nnr:X}KL{nnr:X}KK{nnr:X}{nnr:X}KL{nnr:X}KK{nnr:X}{nnr:X}{nt:H}{ct:Amid} | Stripe4 | Amidation | H | Linear | L | X = sarcosine | 21 | NA | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34164880 | 2021 | K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}{nt:H}{ct:Amid} | Stripe5 | Amidation | H | Linear | L | X = sarcosine | 21 | NA | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 36555393 | 2022 | GIGAVLKVLTTGLP{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 1-14 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 14 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | GIGAVLKVLTTGLPALISWI{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 1-20 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 20 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | VLTTGLPALISWI{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 8-20 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 13 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | VLTTGLPALISWIKR{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 8-22 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 15 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | VLTTGLPALISWIKRKRQQ{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 8-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 19 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | TTGLPALISWIKRKRQQ{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 10-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 17 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | GLPALISWIKRKRQQ{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 12-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 15 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | ALISWIKRKRQQ{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | FITC-melittin 15-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | L | None | 12 | NA | <25 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36555393 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQGGGGSK{d}L{d}A{d}K{d}L{d}A{d}K{d}K{d}L{d}A{d}K{d}L{d}A{d}K{d}{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | melittin-dKLA | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | Mix | None | 45 | NA | 100 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | NA | ||
| 36910465 | 2023 | RFFVPLFLVGILFPAILAKQFTK | ALA‐A1 | Free | Free | Linear | L | None | 23 | NA | 5.6 ± 0.6 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | coil–Helix–coil–Helix | Low hemolytic | ||
| 36910465 | 2023 | RFFVPLFLVGILFPAILAKQFTKC | ALA‐A3 | Free | Free | Linear | L | None | 24 | NA | 1.3± 1.2 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | Helix–coil–Helix | Low hemolytic | ||
| 36910465 | 2023 | LFQISNKLWCKSSQVPQSRN | ALA‐A4 | Free | Free | Linear | L | None | 20 | NA | 0.7 ± 0.6 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | coil | Low hemolytic | ||
| 18584916 | 2008 | FLGTINLSLCEQERDADEEERRDEPDESDVEVEKRFLPIVTNLLSGLLGK{ct:Amid} | Temporin-SHb (Temporin-1Sb) (Temp-1Sb) | Amidation | Free | Linear | L | None | 50 | NA | 50 % Hemolytic at >116µM | Human | Pelophylax Saharicus (Sahara Frog) (Rana Saharica) | Alpha Helix | NA | ||
| 22467870 | 2012 | GEYCGESCYLIPCFTPGCYCVSRQCVNKN{cyc:N-C} | Chassatide C10 (Cyclotide chaC10) | Free | Free | Cyclic | L | None | 29 | NA | 50 % Hemolytic at >25µM | Human | Chassalia Chartacea | NA | Non-hemolytic | ||
| 38110035 | 2024 | GIFSALKTLGKILLPVILPTVAEKIKEKV{ct:Amid} | Myrmicitoxin(1)-Pm6a (MYRTX(1)-Pm6a) | Amidation | Free | Linear | L | None | 29 | NA | 50 % Hemolytic at 614±148nm | Human | Pogonomyrmex Maricopa (Maricopa Harvester Ant) | NA | NA | ||
| 19428765 | 2009 | GLVNGLLSSVLGGGQGGGGLLGGIL | Plasticin-L1 (PTC-L1) | Free | Free | Linear | L | None | 25 | NA | Hemolytic at 500µM | Human | Leptodactylus Laticeps (Santa Fe Frog) | NA | Non-hemolytic | ||
| 10691983 | 2000 | LLPIVGNLLNSLL{ct:Amid} | Temporin-1Td (TD) (Temporin-D) | Amidation | Free | Linear | L | None | 13 | NA | 80 % Hemolytic at 20µM | Human | Rana Temporaria (European Common Frog) | α-Helical | NA | ||
| 24403082 | 2014 | MDPRISSRLRALALLVFVISITDGIPNRAKRSSSEINAEIDGLIQQLTTVDADTKGIQETLTELKTTVSANPSRISQVSAVVKSVGSSLAKFKTGDPYNIVSGCLDILSSIATTYNGPYGVGLGAVASLLSSVIGLFAQDGFKNSLKSIVDEAFKRYRDEELQGQLKGASRTFNDVIGTLKNLTDKDTAVTDLEFSLATSSVSVSQFSNMLGIIESRINTGSTTTDLAEAKRTVDFIFLYLELAVMRETLLTQLILFTKKLGKFENYANGISASIDANKQAVHDTILFLHQMEPKNAVCGAYYYPVHHSDVSEGIFTFTRYFGLPDPPRNTFQGVYRVENRYWPAWHICKESYMGNHMFRGCSYIKSAGVHISALDNGYLKLNLKGKNMYITKHAQGWAWGTADNDPGEQGYFIFVPLKSGYYMISTKKWPNYFVYMESSASGYIRSWHNNPGLQGHWKLT | Toxin CfTX-B (Toxin B) (TX-B) | Free | Free | Linear | L | None | 461 | NA | HU50 % Hemolytic at 5ng/ml | Sheep | Chironex Fleckeri (Australian Box Jellyfish) | NA | NA | ||
| 24403082 | 2014 | MDYAFIVFLVCFVSGTLGNRRRAKRDVDEVTSGINQLVNQLNNVQQDTAAIKSALEELKTEVSASPSTVSQVSEVVNTVGSSLTKFTSGDAFNIVSGCLDLLSTVASTFGGPYGIAISAVISLVSSILSLFAGDGFDSATRKVIEEAFKTHRDQELRDSVNGARRTFNDVIAFLKGASKHGNVTEQELEVISKGVPLTKLSDTLGILESRINRGSTSTDAAEAERTVEFIFLYLQLATMRDTLITNFILILKQVPAADTYANAVSISLDANKESVRETIDFLHNMEAKNAVCGAYYYPIYHSEMTKSILSFAKFFGLPDPPRNTFGGVYRVQNRYWPTWYICKESYMGNHMFRGCSNVRSPSVQIRALENGYQKINLRGKNMYITKHAQGWAWGTADNDPGEQGYFVFVPLKSGYYMISTKKWPNYFVYMESSASGYIRSWNHNPGLQGHWRIL | Toxin CfTX-A (Toxin A) (TX-A) | Free | Free | Linear | L | None | 454 | NA | HU50 % Hemolytic at 5ng/ml | Sheep | Chironex Fleckeri (Australian Box Jellyfish) | NA | NA | ||
| 20097251 | 2010 | MFRIEYSLVQLLLRNVTIPLLLIIQMHIMSSVKLIQIRIWIQYVTVLQMFSMKTKQ | Meucin-25 (BeL-170) (Non-disulfide-bridged peptide 5.2) (NDBP-5.2) | Free | Free | Linear | L | None | 56 | NA | 0 % Hemolytic at 100µM | Mouse | Mesobuthus Eupeus (Lesser Asian Scorpion) (Buthus Eupeus) | NA | NA | ||
| 20632211 | 2011 | MDDSQWVSIHIRDRLAQGNITIRESFLYEGQFHSPEDEKKALTEDDIDQLIIPSEGIGEVCARGRRGSEGWMDLFDGEKKICELHWDNRTKRPSNEFEVIDGDKDYKIECSGWSPQAGPLGHVFIDISAAKKKAAAAAAAK | Terrelysin (Hemolysin) | Free | Free | Linear | L | None | 141 | NA | Hemolytic at 313μg/mL | Sheep | Aspergillus Terreus (Strain Nih 2624 / Fgsc A1156) | NA | NA |